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Abstract
Context: In randomized controlled trials (RCTs), some drugs, including CB1 antagonists for obesity treatment, have been
shown to cause increased suicidal ideation. A key question is whether drugs that increase or are associated with increased
suicidal ideations are also associated with suicidal behavior, or whether drug–induced suicidal ideations are unlinked
epiphenomena that do not presage the more troubling and potentially irrevocable outcome of suicidal behavior. This is
difficult to determine in RCTs because of the rarity of suicidal attempts and completions.
Objective: To determine whether drugs associated with more suicidal ideations are also associated with more suicide
attempts in large spontaneous adverse event (AE) report databases.
Methodology: Generalized linear models with negative binomial distribution were fitted to Food and Drug Administration
(FDA) Adverse Event (AE) Reporting System (AERS) data from 2004 to 2008. A total of 1,404,470 AEs from 832 drugs were
analyzed as a function of reports of suicidal ideations; other non-suicidal adverse reactions; drug class; proportion of reports
from males; and average age of subject for which AE was filed. Drug was treated as the unit of analysis, thus the statistical
models effectively had 832 observations.
Main Outcome Measures: Reported suicide attempts and completed suicides per drug.
Results: 832 drugs, ranging from abacavir to zopiclone, were evaluated. The 832 drugs, as primary suspect drugs in a given
adverse event, accounted for over 99.9% of recorded AERS. Suicidal ideations had a significant positive association with
suicide attempts (p,.0001) and had an approximately 131-fold stronger magnitude of association than non-suicidal AERs,
after adjusting for drug class, gender, and age.
Conclusions: In AE reports, drugs that are associated with increased suicidal ideations are also associated with increased
suicidal attempts or completions. This association suggests that drug-induced suicidal ideations observed in RCTs plausibly
represent harbingers that presage the more serious suicide attempts and completions and should be a cause for concern.
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Introduction
A ‘‘higher rate of ‘suicidal ideation’ has not clearly been shown
to translate into a higher rate of suicide.’’ So wrote Depre ´s and
colleagues when responding to concerns about suicidal ideation for
the obesity drug rimonabant [1].
Suicidal ideation among patients taking certain drugs, including
antiobesity drugs such as the CB1 antagonists rimonabant and
taranabant and the dopamine antagonist ecopipam, have received
much attention in recent years [2–5]. Suicidal behavior presents
itself in a variety of forms, ranging from suicidal ideations to
attempts and completions.
The predictive significance of drug-induced suicidal ideations
remains open to question. In fact, an epidemiologic investigation
of over 5,000 persons followed for 10 years found that, ‘‘Prior
ideation is negatively related, though, to plan ([odds ratio; OR =]
0.4) and attempt ([OR =] 0.2) at follow-up’’ [6]. Thus, it is not
certain that drugs which put patients at increased risk of suicidal
PLoS ONE | www.plosone.org 1 October 2009 | Volume 4 | Issue 10 | e7312ideations also put them at increased risk of suicidal attempts or
completions. In the context of drug development, if a drug
undergoing testing yields reports of suicidal ideations, but no
suicide attempts, should such a drug be taken as presenting a
serious suicide risk to the population at large? This is difficult to
discern because even in relatively large RCTs (e.g., a few thousand
people), it will be very difficult to detect effects on events as rare as
suicides.
The purpose of this study was to use the non-randomized, but far
more numerous AE reports maintained by the FDA to determine
what associations exist, if any, between drugs associated with suicidal
ideations and drugs associated with suicide attempts. The FDA’s
Adverse Event Reporting System (AERS) has been collecting
voluntarily reported AEs since 1969, and does not provide the
‘‘denominator data’’ on the prevalence of drug use in the population.
Nevertheless, one can still employ case-only methodologies to
compare the incidence of differing reactions by drug [7]. We believe
that non-suicidal adverse events serve as a suitable proxy for
denominator data, and they are included as predictors in the model.
AERS provides details of the drugs taken, the reactions, and
demographic information. By adjusting for the total volume of AERs
and demographic variables, it is possible to determine whether there
exists a statistical association between suicidal ideation and attempts.
Methods
Data
We evaluated AERS data from 2004 to 2008, which were freely
available for download from the FDA’s web site [8]. We identified
832 drugs that accounted for 1,404,470 AEs, which covered more
than 99.9% of all AEs that were not recreational or herbal drugs
reported during the time period.
Statistical Methods
The downloaded raw data included files on the drugs taken,
demographic information about the patient, and the reaction. The
files were cross-matched through unique report identifiers in the
‘‘ISR’’ field. The ‘‘primary suspect’’ drugs listed in the drug files
were, depending on the report, listed by their trade names or
generic names; trade names were all converted to generic names
for consistency. Nutritional supplements, recreational drugs, and
herbal drugs were excluded from the analysis. We thus found 832
drugs that accounted for 1,404,470 AERs, an average of 1,688
AERs per drug. The drugs were classified into one or more
indications, as shown in Tables 1 and 2. While the exact
classification of the drugs is in some cases debatable, drug class
served as merely an adjustment in the regression models and was
not the primary focus of this paper. ‘‘Antibiotics’’ were broadly
defined to include antiviral drugs; similarly, ‘‘analgesics’’ included
anesthetics and painkillers.
Through cross-tabulation of the ISR numbers, each report
supplied the patient’s age, gender, and the nature of the reaction.
For each drug, the patient ages and genders were summarized into
mean patient age and percentage of males. The reactions were
divided into ‘‘suicide attempt’’, ‘‘suicide ideations’’, ‘‘suicidal
behavior’’, and ‘‘other’’. Because the meaning of ‘‘suicidal
behavior’’ was not clear to us and such reports were small in
number, they were excluded from regression models.
As a first step, we made log-log scatter plots of suicidal attempts,
ideations, and other AERs (Figure 1). Since many drugs had zero
recorded suicideattempts(454 outof832drugs, or55%), weplotted
against the log of (suicide attempts +1), to avoid the situation where
log(0)=2‘. As can be seen in panel A, when we ran a linear
regression of the log counts, there was a clear positive association
between suicide attempts and ideations. We also plotted suicide
attempts against non-suicidal AERs (panel B), which showed that
suicide attempts increased with the volume of usage. To isolate the
association of ideation with attempts, we found the residuals of the
linear regression from panel B and plotted them against attempts,
which still showed a positive trend (p,.0001).
The association can be established more formally through the
use of multiple regression. We fitted a variety of models, ranging
from multiple linear regressions to generalized linear models, and
all yielded consistent conclusions. Generalized linear models
Table 1. Drug Characteristics.
Drug Category*
Number of
Drugs
Suicide
Attempts
Suicide
Ideations
Suicidal
Behavior
Non-Suicidal
AERs % Male
Mean
Patient Age
AIDS 21 53 44 0 20053 68.6 41.0
Allergy 46 616 448 27 62,395 44.2 47.5
Analgesic 54 4,184 916 22 178,970 43.3 50.2
Antibiotic 133 642 849 14 122,690 48.2 49.2
Anti-Depressant 32 3572 2631 31 77067 40.0 47.9
Anti-inflammatory 58 501 326 10 263,450 43.4 52.9
Anti-psychotic 21 1,426 712 23 63,406 49.9 44.2
Anxiety 29 2256 757 15 33553 37.8 48.8
Cancer 99 130 134 1 167,418 50.8 55.4
Diabetes 21 204 36 0 76,459 50.7 60.5
Heart 110 934 187 7 115,242 53.2 62.8
Muscle Relaxant 45 1,773 681 12 57,989 42.4 46.2
Obesity 7 30 32 5 17079 34.5 39.6
Sleep 14 558 96 5 19,340 44.0 51.1
Total 832 14,351 7,891 193 1,382,035 46.4 52.5
*A drug can belong in more than one category. The ‘‘total’’ line at the bottom is not the sum of the rows above it.
doi:10.1371/journal.pone.0007312.t001
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Category Number of Members Members
AIDS 21 abacavir, amprenavir, atazanavir, darunavir, didanosine, efavirenz, emtricitabine, enfuvirtide, fosamprenavir,
indinavir, lamivudine, lopinavir, nelfinavir, nevirapine, ritonavir, saquinavir, stavudine, tenofovir, tipranavir,
zalcitabine, zidovudine
Allergy 46 albuterol, aminophylline, azelastine, beclomethasone, budesonide, cetirizine, chlorpheniramine, cimetidine,
cromolyn, cyclizine, cyproheptadine, desloratadine, dexchlorpheniramine, diphenhydramine, doxepin,
doxylamine, ephedrine, epinastine, epinephrine, famotidine, fexofenadine, fluticasone, formoterol,
glatiramer, hydroxyzine, ipratropium, ketotifen, levalbuterol, loratadine, meclizine, mianserin, montelukast,
nicardipine, nitric oxide, nitroglycerin, olopatadine, omalizumab, phenyltoloxamine, pirbuterol,
promethazine, salmeterol, terbutaline, terfenadine, theophylline, tiotropium, zafirlukast
Analgesic 54 acetaminophen, acetylsalicylate, acetylsalicylic acid, balsalazide, buprenorphine, butalbital, butorphanol,
celecoxib, codeine, cyanocobalamin, diclofenac, dihydrocodeine, dipyrone, dronabinol, etoricoxib, fentanyl,
gabapentin, hydrocodone, hydromorphone, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic
acid, meloxicam, meperidine, mesalamine, methadone, morphine, nabumetone, nalbuphine, naproxen,
nimesulide, nitrous oxide, opium, oxaprozin, oxycodone, oxymorphone, panadol, pentazocine, pimecrolimus,
piroxicam, pregabalin, propoxyphene, quinine, remifentanil, rofecoxib, salsalate, sufentanil, sulfasalazine,
sulindac, tramadol, valdecoxib, ziconotide
Antibiotic 133 acetylcysteine, acyclovir, adapalene, adefovir, amantadine, amikacin, amoxicillin, amphotericin, ampicillin,
atovaquone, azithromycin, aztreonam, bacitracin, benzoyl peroxide, benzylpenicillin, caspofungin, cefaclor,
cefadroxil, cefazolin, cefdinir, cefepime, cefixime, cefotaxime, cefotiam, cefpodoxime proxetil, cefprozil,
ceftazidime, ceftriaxone, cefuroxime, cephalexin, chloramphenicol, chlorhexidine, chloroquine, ciclopirox,
cilastatin, ciprofloxacin, clarithromycin, clindamycin, clotrimazole, colistin, cyclosporine, cytarabine,
dactinomycin, dalacin, dapsone, daptomycin, daunorubicin, docosanol, doxycycline, econazole, entecavir,
epirubicin, ertapenem, erythromycin, ethambutol, famciclovir, floxacillin, fluconazole, foscarnet,
fosfluconazole, gamimune n, gammagard, ganciclovir, gatifloxacin, gemcitabine, gemifloxacin, gentamicin,
gramicidin, hydroxychloroquine, idarubicin, imipenem, interferon alfacon-1, interferon gamma-1b, isoniazid,
isotretinoin, itraconazole, ivermectin, ketoconazole, lansoprazole, levofloxacin, linezolid, mefloquine,
meropenem, metronidazole, micafungin, miconazole, minocycline, moxifloxacin, mupirocin, neomycin,
norfloxacin, nystatin, ofloxacin, oseltamivir, palivizumab, peg-interferon a-2a ro, penicillin, pentamidine
isethionate, piperacillin, polymyxin b, posaconazole, povidone-iodine, primaquine, pyrazinamide,
pyrimethamine, quinine, rapamycin, ribavirin, rifabutin, rifampin, rifaximin, roxithromycin, selenium sulfide,
sodium polystyrene sulfonate, streptomycin, sulfadiazine, sulfamethoxazole, sulperazone, tazobactam,
tazocilline, telithromycin, terbinafine, tetracycline, tigecycline, tioconazole, tobramycin, trimethoprim,
valacyclovir, valganciclovir, vancomycin, virginiamycin, voriconazole, zanamivir
Anti-Depressant 32 amitriptyline, amoxapine, bupropion, citalopram, clomipramine, cyclobenzaprine, desipramine, dosulepin,
doxepin, duloxetine, escitalopram, fluoxetine, fluvoxamine, imipramine, lithium carbonate, lofepramine,
maprotiline, mianserin, mirtazapine, nefazodone, norepinephrine, nortriptyline, paroxetine, phenelzine,
protriptyline, reboxetine, sertraline, sulpiride, tranylcypromine, trazodone, trimipramine, venlafaxine
Anti-inflammatory 58 abatacept, acetylsalicylate, acetylsalicylic acid, acitretin, adalimumab, allopurinol, alosetron, anakinra,
azathioprine, balsalazide, betamethasone, celecoxib, chloroquine, clobetasol, colchicine, cortisone,
deflazacort, desonide, dexamethasone, dipyrone, drotrecogin alfa, etanercept, etodolac, fludrocortisone,
flunisolide, fluocinonide, flurbiprofen, glatiramer, hydrocortisone, hydroxychloroquine, ibuprofen,
indomethacin, infliximab, interferon beta 1a, ketoprofen, ketorolac, leflunomide, mefenamic acid, meloxicam,
mesalamine, methotrexate, methylprednisolone, mometasone, nabumetone, naproxen, nimesulide,
oxaprozin, pimecrolimus, piroxicam, prednisolone, prednisone, probenecid, rofecoxib, salsalate, sulfasalazine,
sulindac, triamcinolone, valdecoxib
Anti-psychotic 21 amisulpride, aripiprazole, atomoxetine, bromperidol, chlorpromazine, clozapine, fluphenazine, haloperidol,
leponex, olanzapine, paliperidone, perphenazine, pipamperone, prochlorperazine, quetiapine, risperidone,
sulpiride, thioridazine, thiothixene, trifluoperazine, ziprasidone
Anxiety 29 alprazolam, bromazepam, buspirone, carbamazepine, chlordiazepoxide, clobazam, clonazepam, clorazepate,
diazepam, doxepin, doxylamine, duloxetine, estazolam, etomidate, flurazepam, fluvoxamine, gabapentin,
hydroxyzine, lithium carbonate, lorazepam, meprobamate, midazolam, oxazepam, phenelzine, prazepam,
temazepam, tranylcypromine, trazodone, triazolam
Cancer 99 aldesleukin,alemtuzumab, amifostine, anagrelide, anastrozole, arsenic, asparaginase,azacitidine, bevacizumab,
bicalutamide, bleomycin, bortezomib, capecitabine, carboplatin, carmustine, cetuximab, cinacalcet, cisplatin,
cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dasatinib, daunorubicin,
decitabine, docetaxel, doxorubicin, durotep, dutasteride, epirubicin, erlotinib, estrone, estropipate, etoposide,
exemestane,finasteride, fludarabine,fluorouracil,fulvestrant,gamimunen,gammagard,gefitinib,gemcitabine,
gemtuzumab ozogamicin, goserelin, hydroxyurea, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib,
imiquimod, interferon beta 1b, interferon gamma-1b,irinotecan, ixabepilone, lapatinib, lenalidomide,letrozole,
leucovorin, leuprolide, megestrol, melphalan, mercaptopurine, mesna, methotrexate, mitomycin,
mitoxantrone, oxaliplatin, paclitaxel, panitumumab, paricalcitol, pegaspargase, pegfilgrastim, peg-l-
asparaginase, pemetrexed, pentostatin, rituximab, sargramostim, sorafenib, sunitinib, tamoxifen, tamsulosin,
temozolomide, temsirolimus, terazosin, thalidomide, thioguanine, thiotepa, topotecan, toremifene,
tositumomab, trastuzumab, tretinoin, vinblastine, vincristine, vinorelbine, vorinostat
Diabetes 21 acarbose, alpha-glucosidase, aspart, exenatide, gliclazide, glimepiride, glipizide, glucagon, glyburide, insulin,
metformin, miglitol, nateglinide, octreotide, pioglitazone, pramlintide, protamine, repaglinide, rosiglitazone,
sitagliptin, voglibose
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accommodate the discrete nature of count data, as well as
preventing the prediction of negative numbers. GLMs have been
successfully applied to observational mental health studies
involving count data [9]. A typical distribution used for count
data GLMs is the Poisson distribution; however, in the Poisson
distribution the mean of the count data equals its variance. Since
we encountered severe overdispersion, in which the variance of the
data was greater than the mean, we substituted the negative
binomial distribution. The negative binomial substitution is a
common technique applied to overdispersed data [10].
As covariates, we included drug class (e.g., antidepressant;
diabetes drug, etc.), the mean age of patients, and the proportion
of males who experienced AEs on a per-drug basis. Because age and
gender may affect suicide risk, and could possibly create spurious
associations between suicide ideation and attempts, they were
included as covariates to adjust for these demographic factors.
Because drug is the unit of analysis, it is average age and gender of
those whose AE’s reported by drug, rather than individual person
ageorgenderthataremodeled.Tocategorizethe drugsinto classes,
we consulted drug information from the web-based Drug
Information Portal at the U.S. National Library of Medicine. We
used indicator variables for: antidepressant, anxiety, antipsychotic,
heart, antibiotic, AIDS, cancer, allergies, analgesic, anti-inflamma-
tory, diabetes, muscle relaxant, obesity, and sleep aid. For a given
drug, membership in more than one class of drug was possible.
Among the reported reactions, we counted ‘‘completed suicide’’,
‘‘suicide attempt’’, ‘‘intentional overdose’’, and ‘‘multiple drug
overdose intentional’’ as suicide attempts. ‘‘Suicidal ideations’’ were
treatedasa separatepredictorvariable.There wasanotherreaction,
‘‘suicidal behavior’’, but since we could not determine whether this
meant it was an attempt or an ideation, we did not count such
reactions in the primary analysis. The 194 ‘‘suicidal behavior’’
reactions recorded accounted for only 0.01% of all reactions and
were likely to be trivial in effect, so they were excluded from the
primary analysis. However, in a sensitivity analysis, they were
included as suicidal attempts. All other non-suicidal reactions were
counted as ‘‘non-suicidal reactions’’, a predictor variable.
Models were fitted in order of forward selection; starting with an
intercept-only model that had no predictors, successive predictor
variables were added one at a time. Each predictor’s contribution
to the proportion of variation in the outcome was estimated
through Miaou’s pseudo-R
2 (see Appendix S1) [11]. In choosing
which variable to add next, p-value alone was not sufficient, as
several variables had p-values less than .0001. Thus, we chose the
secondary criteria of its effect upon the pseudo-R
2; variables that
explained a greater proportion of variance were added first. In this
way, non-suicidal AERs were chosen first, as they caused the
largest increase in the pseudo-R
2.
During the forward selection process, existing covariates whose
p-values increased to greater than .05 were removed from the
model. In the final stage, a Bonferroni correction was applied to
remove covariates with p-values greater than .05/k, where k is the
number of predictors in the model. This step eliminated variables
whose p-values may have been an artifact of multiple testing.
Results
Descriptive Statistics
The distribution of reported suicide attempts per drug was highly
positively skewed(Figure 2).That is,690 outof 832drugs (83%) had
fewer than 10 attempts reported during this 4-year time period,
while therewas a long tail ofdrugswith 10ormore suicide attempts.
The median number of attempts was 0 attempts per drug, while its
SD was 84 (Table 3). On the high end, there were up to 1,323
suicide attempts out of 27,012 AERs (4.9%) for paroxetine. Suicide
ideations followed a similar positively skewed distribution, with a
median of 0 reported ideations per drug (SD=57.5). On average,
there were more attempts reported than ideations, although there
were 135 drugs (16.2% of drugs) where the number of reported
ideations was greater than attempts. Suicidal ideation would be
expected to be considerably more common than suicidal acts, so
Category Number of Members Members
Heart 110 abciximab, acebutolol, acenocoumarol, acetylsalicylate, acetylsalicylic acid, adenosine, alfuzosin, aliskiren,
amiodarone, amlodipine, atenolol, atorvastatin, benazepril, bendroflumethiazide, betaxolol, bezafibrate,
bisoprolol, bosentan, candesartan, captopril, carvedilol, cerivastatin, chlorthalidone, cholestyramine,
cilostazol, clonidine, clopidogrel, colesevelam, colestipol, digitoxin, digoxin, diltiazem, dipyridamole,
disopyramide, dobutamine, dofetilide, doxazosin, enalapril, eplerenone, epoprostenol, eprosartan, ezetimibe,
felodipine, fenofibrate, flecainide, fluvastatin, fondaparinux, fosinopril, gemfibrozil, glimepiride, guanfacine,
hydralazine, iloprost, ipratropium, irbesartan, isradipine, labetalol, latanoprost, lercanidipine, lidocaine,
lisinopril, losartan, lovastatin, loxen, methyldopa, metolazone, metoprolol, mexiletine, midodrine, minoxidil,
moexipril, moxonidine, nadolol, nebivolol, niacin, nicardipine, nicorandil, nifedipine, nisoldipine, nitric oxide,
nitroglycerin, norepinephrine, olmesartan, pentoxifylline, perindopril, pindolol, pravastatin, prazosin,
propafenone, propranolol, quinapril, ramipril, ranolazine, reteplase, rosuvastatin, simvastatin, sotalol,
telmisartan, terazosin, ticlopidine, timolol, tirofiban, torsemide, trandolapril, treprostinil, trichlormethiazide,
trimetazidine, ursodiol, valsartan, verapamil
Muscle Relaxant 45 acetazolamide, atracurium, baclofen, botox, carbamazepine, carisoprodol, cisatracurium, clidinium, clobazam,
clonazepam, clorazepate, cyclobenzaprine, dantrolene, diazepam, divalproex, estazolam, ethosuximide,
fosphenytoin, gabapentin, glycopyrrolate, lamotrigine, levetiracetam, metaxalone, methocarbamol,
midazolam, orphenadrine, oxcarbazepine, pancuronium, phenobarbital, phenytoin, pregabalin, primidone,
quinine, rocuronium, scopolamine, succinylcholine, temazepam, tetrazepam, tiagabine, tizanidine,
topiramate, trihexyphenidyl, valproic acid, vecuronium, zonisamide
Obesity 7 dextroamphetamine, ephedrine, methamphetamine, orlistat, phentermine, phenylpropanolamine,
sibutramine
Sleep 14 bromazepam, chlordiazepoxide, diphenhydramine, doxylamine, eszopiclone, etomidate, midazolam,
oxazepam, quazepam, ramelteon, triazolam, zaleplon, zolpidem, zopiclone
doi:10.1371/journal.pone.0007312.t002
Table 2. Cont.
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appeared to be reported less often. Overall, suicide attempts and
ideationswere positivelycorrelated(r=+.69,p,.0001);thestrength
of the correlation was stronger than that between suicide attempts
and non-suicidal AERs (r=+.29, p,.0001). The positive associa-
tion remained after adjusting for non-suicidal AERs and other
variables in multiple regression models.
Table 4 provides descriptive statistics for other variables. The
proportion of males who reported a reaction was as low as 0% for
birth control drugs such as norethindrone, to as high as 99% for
vardenafil, an erectile dysfunction drug. A total of 58 drugs (7.0%
of all drugs) had a male proportion of 0% or 100%; some had
gender-specific purposes, while others appeared to be artifacts of
low sample sizes for the drugs.
Inferential Statistics
The changes in R
2 as shown in Table 4 indicate that suicidal
ideations were the single best predictor of suicide attempts,
followed by drug class. Table 5 gives the details of the ‘‘full’’ model
with all significant predictors included. For a negative binomial
regression coefficient, the difference in the logs of expected counts
of the response variable is expected to change by the respective
regression coefficient for each unit increase in the predictor, given
the other predictor variables in the model are held constant.
Specifically, for every reported suicidal ideation per drug, attempts
increased by a log count of .036, or a factor of 3.7% (p,.0001)
with other factors held constant. Non-suicidal AERs also had a
positive association with attempts (p,.0001), but had a much
smaller association of 2.8% for every 100 AERs; a low p-value
does not imply a large magnitude of association. Every reported
ideation was associated with as many as 131 non-suicidal AERs, as
inferred from the coefficients
:0360
:027554=100
&131:
There did exist a negative interaction term between ideations
and non-suicidal AEs; as the volume of non-suicidal AEs rose,
each ideation was associated with a smaller increase in attempts.
Figure 1. Log-log scatter plots.
doi:10.1371/journal.pone.0007312.g001
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Variable Mean Min 1Q Median 3Q Max SD
Number of suicide attempt reports per drug 17.2 0 0 0 5 1323 84
Number of suicide ideation reports per drug 9.5 0 0 0 2 1096 56
Number of non-suicidal reaction reports per drug 1661.1 1 35 235.5 1404 65683 4373
Percent of AE reports by males per drug 46.4% 0% 36% 48% 58% 100% 21%
Mean age of patients reporting AEs per drug 52.5 1.7 44.8 53.0 61.8 88.0 12.6
doi:10.1371/journal.pone.0007312.t003
Figure 2. Distribution of suicide attempts per drug.
doi:10.1371/journal.pone.0007312.g002
Table 4. Model fit statistics.
Model Dispersion Parameter RK
2 DRK
2 p-value at entry
Intercept-only 8.79 0.000 – ,.0001
+ Other* 6.70 0.238 0.238 ,.0001
+ Drug Class 4.68 0.468 0.230 ,.0001
+ Gender 4.23 0.519 0.051 ,.0001
+ Ideation 4.11 0.532 0.014 0.0096
+ Age 4.04 0.540 0.008 0.0217
+ Ideation 6Other 3.88 0.558 0.018 ,.0001
+ Drug Class 6Ideation 3.84 0.564 0.005 0.0005
- Bonferroni Corrections 3.91 0.556 20.008 –
*‘‘Other’’ refers to non-suicidal AEs.
doi:10.1371/journal.pone.0007312.t004
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attempts with other factors held constant. The largest increase in
suicide attempts were seen among drugs when the average age of
patients was 47, and 52% of the reports were from men. This
suggests that drugs used primarily by one gender, children, or old
people were associated with fewer suicide attempts. Intuitively
speaking, birth control pills, prostate drugs, acne medications,
ADHD drugs, growth hormones, or Alzheimer medications are
not typically associated with suicide attempts.
The sensitivity analysis in which ‘‘suicidal behavior’’ reactions
were considered as suicidal attempts yielded essentially identical
results to those of the primary analyses (data not shown).
Discussion
In this paper, we used the strength of the enormous number of
AE reports to estimate the extent to which drugs that have many
suicidal ideations also tend to be drugs that have many suicide
attempts or completions.
There are many limitations to the use of spontaneous AE
reports, including questions about the quality and completeness of
reporting, and the fact that denominator figures (i.e., total number
of people exposed) were not freely available and therefore not
utilized in our study. In this light, it is worth noting that an
additional limitation is that drugs which have other common but
non-suicide related adverse effects could make a ‘signal’ of suicide-
related AE reports looks less noticeable, even when suicides are
common in that drug. One source of denominator data that may
help to overcome these limitations is IMS Health, and future
research should consider merging such data with the type analyzed
herein to evaluate the robustness of our findings [12]. Some drugs
had a high proportion of suicide-related AEs, which was partially
addressed through adjustments for drug class. The study did not
attempt to identify individual drugs that presented a higher risk or
volume of suicide-related AEs per se.
Analyses of AERs can serve as useful complements to RCTs.
RCTs, though more rigorous, generally do not have sufficient
sample sizes to provide estimates of key effects and associations
with rare events. That being said, it is important to note that our
unit of analysis was drug and not person. Thus, our results have no
direct bearing on the extent to which suicidal ideations among
individual persons are predictive of suicidal attempts or comple-
tions among individual persons. The complex interaction between
suicidal attempts and ideations at an individual level is a topic of
ongoing research [13]. By adjusting for the total volume of AERs
and demographic variables, it is possible to determine whether
there remains a statistical association between suicidal ideation
and attempts.
Our analysis shows that after adjusting for non-suicidal AERs,
drug class, and demographic variables on a per drug basis, each
reported suicidal ideation was associated with a 0.035 increase in
the log count of suicide attempts, or a 3.7% increase. These results
support the wisdom of the recent withdrawal of rimonabant from
the market and the discontinuation of CB1 antagonist develop-
ment for obesity research by multiple pharmaceutical companies
including Merck, Pfizer, Solvay, and others. This further suggests,
but does not prove, that drug-induced suicidal ideations in RCTs
may indeed be indicators of a drug that is likely to increase suicidal
attempts and/or completions for some individuals and not be
merely self-limiting reversible epiphenomena.
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Table 5. Estimates of full model.
Variable Raw Coefficient Estimate* SE 95% CI p-value
Intercept 23.699 0.025 1.042 (0.00, 0.19) 0.0004
Ideations 0.036 1.037 0.008 (1.02, 1.05) ,.0001
Other (per 10,000 AERs) .0276 1.028 0.004 (1.02,1.04) ,.0001
Drug Class: Anxiety** 1.468 4.342 0.391 (2.02, 9.34) 0.0002
Drug Class: Antibiotic 21.736 0.176 0.227 (0.11, 0.28) ,.0001
Drug Class: Cancer 21.063 0.345 0.280 (0.20, 0.60) 0.0001
Drug Class: Analgesic 1.826 6.210 0.329 (3.26, 11.84) ,.0001
Drug Class: Anti-inflammatory 21.614 0.199 0.350 (0.10, 0.40) ,.0001
% Male 0.0932 1.098 0.013 (1.07, 1.13) ,.0001
(% Male)
2 20.0009 0.999 0.000 (1.00, 1.00) ,.0001
Mean age 0.123 1.131 0.041 (1.04, 1.23) 0.0027
(Mean age)
2 20.0013 0.999 0.000 (1.00, 1.00) 0.0013
Ideations 6Other 20.0153 0.985 0.003 (0.98, 0.99) ,.0001
Ideations 6Analgesic 20.024 0.976 0.007 (0.96, 0.99) 0.0008
*This is the exponentiated raw coefficient; it is an estimate of the multiplicative factor for the outcome for every unit increase in the predictor.
**Drug classes were coded as indicator variables. It was possible for a given drug to belong to more than one drug class.
doi:10.1371/journal.pone.0007312.t005
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